Acute nonlymphocytic leukemia after treatment of small cell lung cancer

David H. Johnson; Lester L. Porter; Alan F. List; Kenneth R. Hande; John D. Hainsworth; F. Anthony Greco

doi:10.1016/0002-9343(86)90388-8

Acute nonlymphocytic leukemia after treatment of small cell lung cancer

David H. Johnson, Lester L. Porter, Alan F. List, Kenneth R. Hande, John D. Hainsworth, F. Anthony Greco

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

From 1977 to 1982, 377 patients with small cell lung cancer were treated at Vanderbilt University Medical Center. All patients received combination chemotherapy consisting of cyclophosphamide, doxorubicin, and vincristine (CAV) with or without methotrexate, etoposide, and/or hexamethylmelamine. Thoracic and/or prophylactic cranial irradiation was administered to 159 (42 percent) and 192 (51 percent) patients, respectively. Acute nonlymphocytic leukemia was observed in two patients at 22 and 81 months from the start of therapy. The relative risk of leukemia was 154 (95 percent confidence limit, 38 to 293). A Kaplan-Meier estimate of the cumulative probability of leukemia was 1.9 ± 1.4 percent seven years after the start of treatment. The relative risk of leukemia is significantly increased in this group of patients (p <0.0001). Acute nonlymphocytic leukemia is a long-term complication of small cell lung cancer therapy.

Original language	English (US)
Pages (from-to)	962-968
Number of pages	7
Journal	The American Journal of Medicine
Volume	81
Issue number	6
DOIs	https://doi.org/10.1016/0002-9343(86)90388-8
State	Published - Dec 1986

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/0002-9343(86)90388-8

Cite this

@article{2a4711ca622b48efb4c09293a2bda29f,

title = "Acute nonlymphocytic leukemia after treatment of small cell lung cancer",

abstract = "From 1977 to 1982, 377 patients with small cell lung cancer were treated at Vanderbilt University Medical Center. All patients received combination chemotherapy consisting of cyclophosphamide, doxorubicin, and vincristine (CAV) with or without methotrexate, etoposide, and/or hexamethylmelamine. Thoracic and/or prophylactic cranial irradiation was administered to 159 (42 percent) and 192 (51 percent) patients, respectively. Acute nonlymphocytic leukemia was observed in two patients at 22 and 81 months from the start of therapy. The relative risk of leukemia was 154 (95 percent confidence limit, 38 to 293). A Kaplan-Meier estimate of the cumulative probability of leukemia was 1.9 ± 1.4 percent seven years after the start of treatment. The relative risk of leukemia is significantly increased in this group of patients (p <0.0001). Acute nonlymphocytic leukemia is a long-term complication of small cell lung cancer therapy.",

author = "Johnson, {David H.} and Porter, {Lester L.} and List, {Alan F.} and Hande, {Kenneth R.} and Hainsworth, {John D.} and Greco, {F. Anthony}",

note = "Funding Information: From the Division of Medical Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. This work was supported in part by National institutes of Health Grant CA-19429 and American Cancer Society Grant JFCF-714. Dr. Johnson a junior faculty clinical fellow of the American Cancer Society. Requests for reprints should be addressed to Dr. David H. Johnson, Division of Medical Oncology, Department Medicine, MCN A-2127, Vanderbilt University School of Medicine, Nashville, Tennessee 37232. Manuscript submitted November 5,1985, and accepted December IO, 1985.",

year = "1986",

month = dec,

doi = "10.1016/0002-9343(86)90388-8",

language = "English (US)",

volume = "81",

pages = "962--968",

journal = "The American Journal of Medicine",

issn = "0002-9343",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Acute nonlymphocytic leukemia after treatment of small cell lung cancer

AU - Johnson, David H.

AU - Porter, Lester L.

AU - List, Alan F.

AU - Hande, Kenneth R.

AU - Hainsworth, John D.

AU - Greco, F. Anthony

N1 - Funding Information: From the Division of Medical Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. This work was supported in part by National institutes of Health Grant CA-19429 and American Cancer Society Grant JFCF-714. Dr. Johnson a junior faculty clinical fellow of the American Cancer Society. Requests for reprints should be addressed to Dr. David H. Johnson, Division of Medical Oncology, Department Medicine, MCN A-2127, Vanderbilt University School of Medicine, Nashville, Tennessee 37232. Manuscript submitted November 5,1985, and accepted December IO, 1985.

PY - 1986/12

Y1 - 1986/12

N2 - From 1977 to 1982, 377 patients with small cell lung cancer were treated at Vanderbilt University Medical Center. All patients received combination chemotherapy consisting of cyclophosphamide, doxorubicin, and vincristine (CAV) with or without methotrexate, etoposide, and/or hexamethylmelamine. Thoracic and/or prophylactic cranial irradiation was administered to 159 (42 percent) and 192 (51 percent) patients, respectively. Acute nonlymphocytic leukemia was observed in two patients at 22 and 81 months from the start of therapy. The relative risk of leukemia was 154 (95 percent confidence limit, 38 to 293). A Kaplan-Meier estimate of the cumulative probability of leukemia was 1.9 ± 1.4 percent seven years after the start of treatment. The relative risk of leukemia is significantly increased in this group of patients (p <0.0001). Acute nonlymphocytic leukemia is a long-term complication of small cell lung cancer therapy.

AB - From 1977 to 1982, 377 patients with small cell lung cancer were treated at Vanderbilt University Medical Center. All patients received combination chemotherapy consisting of cyclophosphamide, doxorubicin, and vincristine (CAV) with or without methotrexate, etoposide, and/or hexamethylmelamine. Thoracic and/or prophylactic cranial irradiation was administered to 159 (42 percent) and 192 (51 percent) patients, respectively. Acute nonlymphocytic leukemia was observed in two patients at 22 and 81 months from the start of therapy. The relative risk of leukemia was 154 (95 percent confidence limit, 38 to 293). A Kaplan-Meier estimate of the cumulative probability of leukemia was 1.9 ± 1.4 percent seven years after the start of treatment. The relative risk of leukemia is significantly increased in this group of patients (p <0.0001). Acute nonlymphocytic leukemia is a long-term complication of small cell lung cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0022962069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022962069&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(86)90388-8

DO - 10.1016/0002-9343(86)90388-8

M3 - Article

C2 - 3026177

AN - SCOPUS:0022962069

SN - 0002-9343

VL - 81

SP - 962

EP - 968

JO - The American Journal of Medicine

JF - The American Journal of Medicine

IS - 6

ER -

Acute nonlymphocytic leukemia after treatment of small cell lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this